Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

• DOI: 10.3892/or.2015.3876
• Publication Date: 2015-03-23T11:39:56Z
• Authors: Hiroshi Tsukihara; Fumio Nakagawa; Kazuki Sakamoto; Keiji Ishida; Nozomu Tanaka; Hiroyuki Okabe; Junji Uchida; Kenichi Matsuo; Teiji Takechi
• Keywords: Panitumumab; Combination therapy

TAS-102 is a novel oral nucleoside antitumor agent that consists of trifluridine (FTD) and tipiracil hydrochloride (TPI) at molecular ratio 1:0.5, was approved in Japan March 2014 for the treatment patients with unresectable advanced or recurrent colorectal cancer refractory to standard therapies. In present study, we used xenografts assess whether efficacy could be improved by combining it bevacizumab, cetuximab panitumumab. orally administered twice day from 1 14, panitumumab were intraperitoneally week 2 weeks. Growth inhibitory activity evaluated based on relative tumor volume (RTV) after weeks drug administration time taken increase five-fold (RTV5). Tumor growth inhibition RTV5 bevacizumab combination significantly better than those alone SW48 HCT116 models, concentration phosphorylated FTD tumors determined liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis higher group monotherapy group. The also more effective either model. There no significant difference body weight between mice treated any therapies 29. Our preclinical findings indicate therapy TAS-102, promising option cancer.